Merck & Co. has received full FDA approval for Keytruda in combination with Lenvima, a tyrosine kinase receptor inhibitor from Eisai. This drug combination is now permanently approved for the treatment of patients with advanced endometrial carcinoma who do not have microsatellite instability or mismatch repair defects. Previously, approval under an expedited approval process was in effect.